Maria Artiles
Family · Orlando, FLNPI 1124860465
Payments from drug & device makers
Across 103 payments — averaging $22.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$519
- Acadia Pharmaceuticals Inc$287
- Lilly USA, LLC$244
- Neurocrine Biosciences, Inc.$170
- Pfizer$166
- Lundbeck LLC$156
- plus $808 from 14 others
What the payments were for
- Food & beverage$2,350100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 25 | $519 |
| Acadia Pharmaceuticals Inc | 15 | $287 |
| Lilly USA, LLC | 8 | $244 |
| Neurocrine Biosciences, Inc. | 6 | $170 |
| Pfizer | 8 | $166 |
| Lundbeck LLC | 6 | $156 |
| Teva Pharmaceuticals USA, Inc. | 7 | $153 |
| Amneal Pharmaceuticals LLC | 5 | $118 |
| UCB, Inc. | 4 | $102 |
| Eisai Inc. | 4 | $101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $67 |
| MDD US Operations, LLC | 3 | $61 |
| Medtronic | 3 | $53 |
| Genentech USA, Inc. | 1 | $28 |
| Grifols USA, LLC | 1 | $23 |
| DJO, LLC | 1 | $23 |
| Biogen | 1 | $21 |
| Tanabe Pharma America, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KISUNLA$111
How this compares
$2,350 in reported general payments places this provider in the 80th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GocovriAmantadine Hcl | 17 | $55,806 |
| UbrelvyUbrogepant | 14 | $19,214 |
| RytaryCarbidopa/Levodopa | 17 | $18,246 |
| Rivastigmine | 18 | $2,022 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 65 | $1,325 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 29 | $566 |
| Memantine Hcl | 21 | $538 |
| Gabapentin | 24 | $194 |
| Donepezil Hcl | 20 | $176 |
| Tizanidine Hcl | 18 | $101 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MDD US Operations, LLCGocovri | $61 | $55,80617 claims |
| AbbVieUbrelvy | $519 | $19,21414 claims |
| Amneal Pharmaceuticals LLCRytary | $118 | $18,24617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 14,618 family providers in Florida.
Other family in Orlando
- Donna OrtizOrlando$417K
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.